• All
• Day 1: March 27 (Thu)
• Day 2: March 28 (Fri)
• Day 3: March 29 (Sat)

Day 2: March 28 (Fri)

• Beyond BCR::ABL1 - the role of genomic analysis in the management of CML Susan Branford
  Centre for Cancer Biology, SA Pathology, Australia CV Abstract
• Next-generation sequencing (NGS) in CML Jieun Kim
  Soonchunhyang University College of Medicine, Korea CV Abstract
• What systems biology and AI can teach us about the pathogenesis and therapy of CML Richard A. Van Etten
  University of California, Irvine, USA CV Abstract
• Beyond BCR::ABL1 RQ-PCR in CML Hawk Kim
  Gachon University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Chronic inflammation as a driver of TP53-mutant leukemic evolution Yan Liu
  Northwestern University Feinberg School of Medicine, USA CV Abstract
• TP53 copy number and protein expression for risk stratification in AML Joseph D. Khoury
  University of Nebraska Medical Center, USA CV Abstract
• Molecular characterization of TP53 mutation in AML and high-risk MDS Peter J.M. Valk
  Erasmus University Medical Center, The Netherlands CV Abstract

Day 2: March 28 (Fri)

• Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: The emerging role of ponatinib and the shift away from allogeneic hematopoietic stem cell transplantation Jae-Ho Yoon
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia Jae Park
  Memorial Sloan Kettering Cancer Center, USA CV Abstract
• Navigating new horizons: Safety and efficacy of CD7-CAR-T cells in T-ALL/LBL Yongxian Hu
  The First Affiliated Hospital of College of Medicine, Zhejiang University, China CV Abstract

Day 2: March 28 (Fri)

• MRD-based therapeutic decisions in AML Dae Hun Kwag
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• MRD-based therapeutic decisions in pediatric ALL Jung Yoon Choi
  Seoul National University College of Medicine, Korea CV Abstract
• MRD-based therapeutic decisions in MM Ji Hyun Lee
  Dong-A University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Evolutionary Legacy in Science and Clinical Medicine of Human CD38, a Catalytic Signaling Receptor Fabio Malavasi
  University of Torino, Italy CV Abstract

Day 2: March 28 (Fri)

• Immunoglobulin Therapy in Immunocompromised Patients Undergoing SCT, CAR T-Cell, or Bispecific Antibody Treatment Gi June Min
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 28 (Fri)

• Reshaping Mantle Cell Lymphoma Treatment: Evidence from the Triangle and Sympatico Studies Gyeong-Won Lee
  Gyeongsang National University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Romiplostim Across the Spectrum: A Comprehensive Analysis from ITP Management to Aplastic Anemia Treatment Young Hoon Park
  Ewha Womans University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Real-World Evidence on How to Use Epcoritamab in 3L+ DLBCL Georg Lenz
  Munster University Hospital, Germany CV Abstract

Day 2: March 28 (Fri)

• Scemblix Experience in Post 2 TKI Setting and the Newly Diagnosed Setting Michael J. Mauro
  Memorial Sloan Kettering Cancer Center, USA CV Abstract

Day 2: March 28 (Fri)

• Treatment strategies for transplant-eligible newly diagnosed multiple myeloma Ja Min Byun
  Seoul National University College of Medicine, Korea CV Abstract
• Treatment of transplant-ineligible multiple myeloma Jongheon Jung
  National Cancer Center, Korea CV Abstract
• Supportive care of multiple myeloma patients in the new agent era: Optimizing outcomes beyond therapy Sung-Soo Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 28 (Fri)

• Overcoming aggressive pediatric non-Hodgkin lymphoma Birgit Burkhardt
  University Hospital Münster, Germany CV Abstract
• Utilizing NGS MRD as an effective tool in ALL management Yongmin Tang
  Children’s Hospital of Zhejiang University School of Medicine, China CV Abstract
• CAEBV, from basic to updated therapeutic options Seung Min Hahn
  Yonsei University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Current status of "off-the-shelf" allogeneic CAR in the treatment of acute lymphoblastic leukemia Reuben Benjamin
  King’s College London, UK CV
• Allogeneic CAR-T cells engineered with gene-editing strategies for the treatment of B-cell non-Hodgkin lymphomas Boyu Hu
  University of Utah, USA CV Abstract
• Memory-like NK cells armed with a neoantigen-specific CAR Rizwan Romee
  Harvard Medical School, USA CV Abstract

Day 2: March 28 (Fri)

• Anemia Eun sang Yu
  Korea University College of Medicine, Korea CV
• Thrombocytopenia Yoo Jin Lee
  Ulsan University Hospital, Korea CV Abstract
• Neutropenia Seonggyu Byeon
  Gachon University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Current status of CAR-T treatment in Taiwan Tai-Chung Huang
  National Taiwan University Hospital, Taiwan CV Abstract
• Challenges and opportunities in CAR-T treatment in Singapore William YK Hwang
  National Cancer Centre Singapore, Singapore CV Abstract
• Developments of CAR-T cell therapy for multiple myeloma in China Kailin Xu
  The Affiliated Hospital of Xuzhou Medical University, China CV Abstract
• Present and future of CAR-T therapy in Korea Dok Hyun Yoon
  University of Ulsan College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Minimal (measurable) disease in hematologic malignancy James L. Zehnder
  Stanford University School of Medicine, USA CV Abstract
• Exploring the transcriptional and protein landscape of immune cells with CITE-seq Jennifer A. Foltz
  Washington University School of Medicine, USA CV Abstract
• Comprehensive resistance profiling of ABL1 variants against various kinase inhibitors using prime editing Hyongbum Henry Kim
  Yonsei University College of Medicine, Korea CV Abstract

Day 2: March 28 (Fri)

• Finding a better immunosuppressive treatment in SAA Fengkui Zhang
  Chinese Academy of Medical Sciences and Peking Union Medical College, China CV Abstract
• Alternative donor HSCT in SAA Ho Joon Im
  University of Ulsan College of Medicine, Korea CV Abstract
• Optimal treatment of PNH in the era of proximal complement inhibitors Rosario Notaro
  Core Research Laboratory, ISPRO, Italy CV Abstract

Day 2: March 28 (Fri)

• Immunotherapy in follicular lymphoma Gi June Min
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• BTK inhibitions in Waldenström’s macroglobulinemia Myung-won Lee
  Chungnam National University College of Medicine, Korea CV Abstract
• Treatment for older patients with Hodgkin lymphoma Hyunsoo Cho
  Yonsei University College of Medicine, Korea CV Abstract